MannKind (MNKD) Corporate presentation summary

Strategic focus and innovation

• Emphasizes patient-centric solutions for cardiometabolic and orphan lung diseases, leveraging innovative drug delivery platforms.

• Key pillars include Tyvaso DPI, FUROSCIX, and Afrezza, each targeting significant unmet needs and growth opportunities.

• Technosphere technology underpins two FDA-approved products, enabling efficient deep lung drug delivery.

Product portfolio and pipeline

• FUROSCIX offers a wearable, at-home diuretic for CHF/CKD, with strong revenue and dose growth; ReadyFlow autoinjector could further expand market reach pending 2026 approval.

• Afrezza, an inhaled insulin, is recognized in ADA 2026 guidelines and is positioned for pediatric expansion with a PDUFA date in May 2026.

• Tyvaso DPI continues to drive revenue growth, with new formulations and expanded collaboration with United Therapeutics.

• Nintedanib DPI is advancing in Phase 2 for IPF, targeting a market with high unmet need due to current therapy limitations.

Financial performance and market opportunity

• FUROSCIX net revenue reached $47.1M YTD Q3 2025, up 93% YoY, with 61,407 doses dispensed, up 153% YoY.

• Afrezza net revenue was $51.7M YTD Q3 2025, up 23% YoY, with 31% YoY growth in new prescriptions.

• Tyvaso DPI-related revenue was $954M YTD Q3 2025, up 22% YoY, with Q3 revenue of $59M, up 15% from Q3 2024.

• Each 10% pediatric share for Afrezza could yield ~$150M in revenue; every 100K FUROSCIX patients is ~$350M in revenue.